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Introduction
There are an estimated 13,430 new cases of laryngeal 
squamous cell carcinomas (LXSCC) diagnosed each year 
in the U.S [1]. Advanced stage LXSCC is treated with 
radiation or chemoradiation, with current strategies 
favoring organ- sparing approaches to reduce comorbidity 
[2]. Despite well- established multimodality protocols, 
locoregional failure remains at 20–30% [3]. Whereas the 
detection of human papillomavirus (HPV) is an important 
predictor of clinical outcome in oropharyngeal squamous 
cell carcinomas (OPSCC) [4], HPV is much less prevalent 
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Abstract
We previously reported a novel association between CDKN2A nonpromoter 
methylation and transcription (ARF/INK4a) in human papillomavirus associated 
oropharyngeal tumors. In this study we assessed whether nonpromoter CDKN2A 
methylation in laryngeal squamous cell carcinomas (LXSCC) conferred a similar 
association with transcription that predicted patient outcome. We compared 
DNA methylation and ARF/INK4a RNA expression levels for the CDKN2A 
locus using the Illumina HumanMethylation27 beadchip and RT- PCR in 43 
LXSCC tumor samples collected from a prospective study of head and neck 
cancer patients treated at Montefiore Medical Center (MMC). Validation was 
performed using RNAseq data on 111 LXSCC tumor samples from the Cancer 
Genome Atlas (TCGA). The clinical relevance of combined nonpromoter CD-
KN2A methylation and transcription was assessed by multivariate Cox regression 
for locoregional recurrence on a subset of 69 LXSCC patients with complete 
clinicopathologic data from the MMC and TCGA cohorts. We found evidence 
of CDKN2A nonpromoter hypermethylation in a third of LXSCC from our 
MMC cohort, which was significantly associated with increased ARF and INK4a 
RNA expression (Wilcoxon rank- sum, P = 0.007 and 0.003, respectively). A 
similar association was confirmed in TCGA samples (Wilcoxon rank- sum test 
P < 0.0001 for ARF and INK4a). Patients with CDKN2A hypermethylation or 
high ARF/INK4a expression were significantly less likely to develop a locoregional 
recurrence compared to those with neither of the features, independent of other 
clinicopatholgic risk factors (adjusted hazard ratio=0.21, 95% confidence inter-
val:0.05–0.81). These results support the conclusion that CDKN2A nonpromoter 
methylation is associated with increased ARF and INK4a RNA expression, and 
improved locoregional control in LXSCC.
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in LXSCC [5], and there are no molecular or genomic 
biomarkers to guide treatment selection for LXSCC patients.
Recently, our group identified a novel association between 
methylation in the nonpromoter region of CDKN2A and 
increased p16(INK4a) expression in HPV- positive OPSCC 
[6]. The CDKN2A gene, located at chromosome 9p21, 
encodes two distinct tumor suppressor proteins, INK4a 
and ARF. While the transcripts overlap, they each incor-
porate a unique first exon and different reading frames 
[7]. Furthermore, whereas both CDKN2A proteins are 
known to induce cell cycle arrest and are commonly dis-
rupted during tumorigenesis [7], p16(INK4a) expression 
is not common in LXSCC and is not predictive of clinical 
outcome [8]. However, the expression of ARF is being 
assessed as a therapeutic alternative in HPV- negative head 
and neck cancer [9]. We hypothesized that nonpromoter 
hypermethylation of CDKN2A and associated transcription 
may occur in a subset of less aggressive LXSCC.
To test this hypothesis, we examined patients with 
LXSCC enrolled in an ongoing research program at a 
large urban health center to measure CDKN2A nonpro-
moter methylation and transcription in tumors. We assessed 
whether increased methylation and expression of the 
CDKN2A region was associated with locoregional control 
in these patients. We validated our findings in an inde-
pendent sample of LXSCC tumors with genetic, epigenetic, 
and transcriptomic data from the Cancer Genome Atlas 
(TCGA; http://cancergenome.nih.gov/) [10].
Methods
Patient tissue samples
Initial analyses were based on 43 histologically confirmed 
LXSCC tumors obtained by biopsy or surgical resection 
from patients undergoing treatment at MMC in Bronx, 
NY between 2002 and 2010. All patients provided written 
consent for participation in this study under a protocol 
approved by the Institutional Review Board at MMC. All 
tumors were assessed histologically to ensure a majority 
of tumor cells in samples. Tumor samples were snap- 
frozen in liquid nitrogen within 30 min and kept at −80°C 
until DNA and RNA analysis. This cohort served as our 
discovery sample set.
All tumor samples were tested for HPV- 16 RNA using 
a Real- Time Reverse Transcription- Polymerase Chain 
Reaction (qRT- PCR) assay described previously [11]. 
Tumors with high E6 and/or E7 RNA expression (∆CT 
≥100- fold compared to GAPDH) were considered HPV- 
positive. Presence of p16(INK4a) protein was also assayed 
using a clinically available immunohistochemistry (IHC) 
antibody (BD Biosciences, San Jose, CA; Cat. no. 551154) 
[8]. Briefly, p16 staining was done for formalin- fixed and 
paraffin- embedded tumor section. Tumors were considered 
p16- positive if >50% of the tumor cells exhibited strong 
nuclear staining.
Methylation analyses
The protocol for measuring DNA methylation using micro-
arrays was as described previously [11]. For methylation 
analysis, HumanMethylation27 beadchip (Illumina, San 
Diego, CA) beta values were transformed to normalized 
M- values using an established protocol [12]. The previ-
ously described nonpromoter region included one CpG 
within exon 3 (cg11653709) and three CpGs within the 
preceding intron (cg07752420, cg09099744, and 
cg10895543) [6]. In addition to the nonpromoter region, 
we assessed methylation levels for 3 CpG loci within the 
ARF promoter of CDKN2A (cg00718440, cg03079681, and 
cg26673943). We also tested adjacent normal tissues from 
48 LXSCC patients but found consistently low levels of 
methylation overall in all samples (data not shown).
RNA expression analyses
Expression levels for ARF and INK4a were quantified from 
total RNA (100 ng) of 29 LXSCC tumors using real- time 
reverse transcriptase- PCR (qRT- PCR) Taqman® probes and 
the TaqMan RNA- to- Ct™ 1- Step Kit (Applied Biosystems, 
Waltham, MA). Resulting cycle threshold (Ct) values were 
normalized to GAPDH and subsequently converted to 
relative expression (2−ΔΔCT) values.
As an additional platform, whole- genome expression 
microarray data from a prior analysis of head and neck 
tumors were also assessed [11] and 21 of the LXSCC sam-
ples used for the methylation analysis were used in this 
analysis. TRIzol (Ambion, Austin, TX) extracted RNA 
(500 ng) for each tumor sample was amplified and biotin 
labeled using the Illumina TotalPrep RNA Amplification 
Kit (Ambion, Austin, TX). Messenger RNA expression levels 
were subsequently analyzed by RNA hybridization to the 
Illumina HumanHT- 12- v3 Expression BeadChip (Illumina, 
San Diego, CA). Microarray probes for the CDKN2A gene 
were identified using the RefSeq database release 17 and 
UniGene build 188. RNA expression levels were assessed 
by a probe targeting ARF and a combined CDKN2A probe. 
In addition, a probe corresponding to the INK4b gene in 
the adjacent CDKN2B region was also identified and used 
to measure corresponding expression of that transcript.
TCGA data and analyses
Publically available genomic data from The Cancer Genome 
Atlas (TCGA) head and neck cancer project were utilized 
as a validation set for these studies [10]. CDKN2A 
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methylation, RNA expression, and patient clinical data 
were mined for 111 LXSCC tumor samples from the 
TCGA database. Per TCGA protocol, only samples with 
>60% tumor cells were included for analysis. One CpG 
(cg12840719) located within the same downstream non-
promoter region of the CDKN2A gene was captured by 
the HumanMethylation 450K beadchip (Illumina, San 
Diego, CA) array used by TCGA. We previously showed 
this region to exhibit consistent methylation patterns across 
neighboring CpGs [6].
Other data extracted from TCGA included RNA expres-
sion and genetic mutation events corresponding to the 
CDKN2A gene. Reads Per Kilobase per Million mapped 
reads (RPKM) for ARF, INK4a, Cylcin A, Cyclin E, and 
INK4b from TCGA were used to measure gene expression 
levels generated by RNAseq [10]. HPV expression status 
was determined using E6 and E7 RNAseq data [10]. In 
addition, level 3 copy number variation (CNV) data for 
9p21 and the CDKN2A locus, and level 3 somatic muta-
tion data for CDKN2A and TP53 were mined for all 
TCGA LXSCC samples [10].
Statistical analyses
For efficiency and purposes of statistical validation, the 
MMC discovery cohort samples were divided into two 
groups based on CDKN2A methylation levels (hypo- and 
hyper- methylated) using Euclidean distance hierarchical 
clustering with complete linkage using all 4 CpG loci. 
The corresponding methylation heatmap was visualized 
using the supraHex v1.8.0 R package [13]. To allow for 
statistical comparison, grouping of the TCGA samples was 
based on the distribution of M- values for the single down-
stream CDKN2A CpG (cg12840719) assayed by the 
HumanMethylation 450K beadchip assuming a cutoff for 
hypermethylation based on the same percentile threshold 
of 32% observed in our discovery sample of LXSCC tumors 
from MMC (M = −0.048). CpG loci located at the pro-
moters of ARF and INK4a transcripts were also assessed 
from TCGA data.
With respect to the expression data, MMC samples were 
grouped based on median RNA values for each transcript 
excluding LXSCC tumors with no detectable RNA, with 
relative expression thresholds of 49 (ΔΔCT) for ARF and 
166 (ΔΔCT) for INK4a. The cut- off selection for ARF and 
INK4a expression in TCGA samples was similarly based 
on median RNA levels excluding tumors with no detect-
able RNA (with a corresponding RPKM of 171 for ARF 
and 35 for INK4a). This was done to differentiate between 
tumors with high and low RNA expression.
Wilcoxon rank sum tests were used to determine the 
statistical significance of observed differences in CDKN2A 
transcript levels between tumors with hypo- or 
hypermethylated CDKN2A. Box- and- Whisker plots were 
generated using the ggplot2 v2.0.0 R package [14]. We 
used contingency tables to assess the associations between 
CDKN2A locus methylation/expression status (i.e., com-
paring tumors with high vs. low CDKN2A methylation/
expression) and clinicopathologic factors at diagnosis, and 
tested using Chi- square or Fisher Exact test statistics, where 
appropriate. All tests were two- sided.
In addition to the 29 patients followed at MMC, infor-
mation on clinical outcome was ascertained for 69 LXSCC 
patients originating from three collaborating TCGA tissue 
collection sites: the University of Pittsburgh (n = 23), 
Vanderbilt University (n = 9), and the University of North 
Carolina (UNC) at Chapel Hill (n = 8). Response to treat-
ment was based on locoregional recurrence, defined as a 
recurrence of cancer at the primary site or regional lymph 
nodes. The association between CDKN2A locus methylation/
expression and time to locoregional recurrence was assessed 
using Kaplan–Meier survival analyses, and strata were com-
pared using Log- rank test statistics. Multivariable Cox regres-
sion models were built, adjusting a priori for gender, age 
(<60 vs. ≥60 years) and regional lymph node metastases 
[15] [node negative (N0) vs. regional lymph node metastasis 
(N+)]. Other clinicopathologic variables assessed included 
treatment (coded as unimodality treatment [radiation or 
surgery], surgery plus postoperative adjuvant treatment 
[radiation or chemoradiation], and primary chemoradiation), 
overall stage [16] and tumor size [15] (I/II vs. III/IV), 
smoking status (current vs. former smoker), and HPV status. 
All models were stratified by sample cohort (MMC vs. 
TCGA) in order to adjust for possible bias associated with 
tissue acquisition protocols for the different studies and 
methylation platforms. A parsimonious model was derived 
using backward elimination for variables with P < 0.05. 
Effect modification (e.g., with clinical factors and study site) 
was tested for by including cross- product terms into the 
model. The potential for confounding was also assessed 
using a change in point criterion [17]. Proportional hazards 
assumptions were tested using log- log plots, observed versus 
expected plots, and goodness- of- fit tests. Kaplan–Meier plots 
were generated using the Survival v2.38.3 R package[18], 
and multivariable Cox regression analyses were performed 
using Stata v.14 (StataCorp, College Station, TX).
Results
A subset of LXSCC tumors exhibit CDKN2A 
nonpromoter methylation
We first set out to identify CDKN2A nonpromoter meth-
ylation differences between LXSCC tumors. Using hier-
archical clustering, 43 primary tumor samples from patients 
treated at MMC were clustered by the methylation array 
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data for four CpGs within the downstream nonpromoter 
region of CDKN2A (Fig. 1). Two clusters of tumors were 
identified with approximately a 2- to- 1 ratio with hypo- 
and hypermethylation.
By clustering the methylation values for the four non-
promoter CpGs, we were able to compare LXSCC tumors 
with and without CDKN2A methylation. The clinical 
characteristics for the MMC patients included in our 
analyses are summarized in Table S1. Hypermethylated 
LXSCC tumors were more likely to have p16(INK4a) 
protein expression as measured by IHC compared to 
hypomethylated tumors (Fisher’s Exact test P = 0.029). 
In contrast, the prevalence of HPV was much lower and 
showed no significant association with CDKN2A methyla-
tion (P = 1.0). No significant differences were observed 
with respect to other clinicopathologic factors between 
the hyper- and hypomethylated groups.
CDKN2A nonpromoter methylation is 
associated with ARF and INK4a RNA 
expression
As we did previously for OPSCC, we also examined the 
relationship between CDKN2A nonpromoter methylation 
and RNA expression in LXSCC. We measured RNA levels 
for INK4a and ARF by qRT- PCR in 29 LXSCC tumors. 
The clinical characteristics for the patients with qRT- PCR 
data are summarized in Table S2. Increased levels of both 
ARF and INK4a were found in tumors with CDKN2A 
hypermethylation compared to those without (Wilcoxon 
rank- sum test P = 0.007 and 0.003, respectively; Fig. 2). 
RNA levels for these transcripts were also measured using 
the Illumina expression array as an alternative platform 
for validation. Of the 33 LXSCC tumors analyzed using 
the Illumina expression array, 26 were also assayed by 
qRT- PCR. Consistent with the qRT- PCR results, ARF and 
Figure 1. Cluster analysis of laryngeal tumor samples based on CDKN2A nonpromoter methylation. The M- values of 4 CpGs from the downstream 
nonpromoter region of CDKN2A were heirarchically clustered for 43 primary LXSCC tumors. Each leaf in the dendrogram represents a sample, and 
each row represents an individual CpG loci. Two main clusters were identified based on the dendrogram above the heatmap. Samples in the left, 
mostly green cluster, were categorized as the hypomethylated group (n = 29), and the samples in the right, mostly red cluster, were categorized as 
the hypermethylated group (n = 14). HPV RNA, p16(INK4a) protein expression (by IHC), and smoking status for each sample are shown below the 
heatmap. White squares indicate HPV RNA negative, p16(INK4a) protein negative and noncurrent smokers, respectively. Black squares indicate HPV 
RNA positive, p16(INK4a) protein positive and current smokers, respectively. Missing data are denoted by an “X”. A color key matching color with 
corresponding M- value is shown in the upper left corner. HPV, human papillomavirus; IHC, immunohistochemistry.
Figure 2. Overexpression of CDKN2A transcripts in laryngeal tumor 
samples with CDKN2A nonpromoter methylation. Relative mRNA 
expression values obtained by qRT- PCR for ARF and INK4a were plotted 
by tumor methylation status on a Log10 scale. Eighteen hypomethylated 
LXSCC tumors were compared to 11 hypermethylated tumors for each 
transcript. Increased levels of ARF (Wilcoxon rank- sum, P = 0.0068) and 
INK4a (P = 0.003) were seen in the hypermethylated groups.
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CDKN2A RNA levels were increased in tumors with non-
promoter CDKN2A hypermethylation (P < 0.0001 for 
both probes; Fig. S1).
ARF and INK4a RNA levels were also plotted against 
the methylation M- values for each of the four nonpro-
moter CpG loci tested on the Illumina methylation array 
revealing significant positive correlations with ARF and 
INK4a transcription (Figs S2 and S3). Methylation of CpG 
loci within the promoter region of ARF were also meas-
ured, but these showed no evidence of methylation and 
no correlation with corresponding RNA expression (data 
not shown). Together, these data indicate that increased 
ARF and INK4a RNA levels are associated with CDKN2A 
nonpromoter hypermethylation.
TCGA LXSCC tumors validate our 
methylation and expression results
To validate our results from the MMC cohort, we analyzed 
CDKN2A nonpromoter methylation and RNA levels for 
111 LXSCC tumors available in the TCGA database. Table 
S3 summarizes the clinical characteristics for the patients 
in TCGA. Unlike the Illumina HumanMethylation27 bead-
chip array used in our MMC study, which assayed four 
downstream nonpromoter CDKN2A CpG loci, collection 
of DNA methylation data for TCGA samples utilized the 
Illumina HumanMethylation 450K beadchip platform, 
which assayed only one novel CpG within the region of 
interest. For consistency, we selected an M- value cutoff 
based on the distribution in methylation observed for the 
MMC cohort (see Methods for cutoff); ARF and INK4a 
RNA levels were plotted against CpG M- values to dem-
onstrate the correlation between hypermethylation and 
increased RNA levels for CDKN2A expression (Fig. S4).
We compared the CDKN2A RNA levels obtained by 
RNAseq for 75 samples that were classified as hypo-
methylated and 36 samples that were hypermethylated 
(Fig. 3). The hypermethylated LXSCC tumors exhibited 
an increase in both ARF and INK4a RNA compared to 
hypomethylated tumors (Wilcoxon rank- sum test 
P < 0.0001 for both transcripts), confirming the results 
seen in our MMC cohort. Alternative cutoffs were evalu-
ated, but moving the methylation threshold by one 
standard deviation (equivalent to −1.7 M- values) did 
not affect our results. In addition, we were able to assess 
the methylation levels for the promoter regions of both 
CDKN2A transcripts, which were uniformly unmethyl-
ated, ruling out the possibility that the lack of CDKN2A 
RNA in hypomethylated tumors was due to promoter 
methylation. As such, data from TCGA LXSCC tumors 
validated our MMC findings that CDKN2A nonpromoter 
methylation was associated with ARF and INK4a RNA 
expression.
Tumors with high CDKN2A expression 
exhibit CDKN2A and/or TP53 mutations
Given that the CDKN2A locus encodes two tumor sup-
pressors, and that both transcripts are elevated in LXSCC 
tumors, we wanted to examine the presence of genetic 
variations across this locus. Data available from TCGA 
allowed for the assessment of genetic alterations, including 
9p21 CNV, CDKN2A mutation status, and p53 mutation 
status (Fig. 4). As expected, tumors with homozygous 
deletions for CDKN2A were only observed in the group 
with low CDKN2A RNA, and in the majority of the 
hypomethylated LXSCC. However, 58% of hypomethylated 
tumors with low CDKN2A RNA expression had at least 
one copy of CDKN2A. Moreover, at least one copy was 
retained for all tumors with high levels of ARF and INK4a 
RNA, and 75% of the hypermethylated tumors retained 
both copies. Many tumors with high levels of CDKN2A 
RNA also exhibited mutations within the CDKN2A (22%) 
and/or TP53 (89%) loci. All the CDKN2A mutations were 
seen within the first exon of the INK4a transcript (exon 
1α) and the shared exon 2, and there were no mutations 
within the first exon of the ARF transcript (exon 1β). 
These data suggest that despite high levels of ARF and 
INK4a RNA, mutations within the CDKN2A and TP53 
loci may be a hindrance toward fully functional tumor 
suppressors.
Figure 3. Overexpression of CDKN2A transcripts in hypermethylated 
TCGA laryngeal tumors. RNAseq expression values for ARF and INK4a 
were plotted for 111 primary LXSCC tumors from the TCGA cohort. 
Seventy- five hypomethylated tumors were compared to 36 
hypermethylated tumors with the expression levels plotted on a Log10 
scale. We observed an increase in ARF (Wilcoxon rank- sum, P < 0.0001) 
and INK4a (P < 0.0001) expression for the hypermethylated groups.
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RNA levels of E2F targets remain unaffected 
by CDKN2A nonpromoter methylation
Since INK4a acts as an inhibitor of E2F transcription 
factors, we also examined the RNA expression levels of 
two E2F targets, Cyclin A and Cyclin E. RNAseq data 
were obtained from TCGA data for 111 laryngeal tumors, 
and we compared RNA levels of Cyclin A and Cyclin E 
for 75 tumors with CDKN2A hypomethylation and 36 
tumors with CDKN2A hypermethylation (Fig. S5). We 
found no significant differences in Cyclin A or Cyclin E 
RNA expression between the two groups. While these 
analyses did not directly measure the functionality of 
INK4a, the results suggest normal E2F activity for both 
groups of laryngeal tumors.
RNA expression of INK4b is also associated 
with CDKN2A nonpromoter methylation
There is a possibility that the association between CDKN2A 
methylation and RNA expression may be a consequence 
of chromatin conformation with more of a regional effect 
on gene expression. As a preliminary test for this hypoth-
esis, we examined the RNA expression for an adjacent 
locus (CDKN2B) found at chromosome 9p21. We assessed 
RNA levels for the INK4b gene, which is transcribed from 
the CDKN2B locus, in both MMC and TCGA cohorts. 
For the MMC samples, RNA levels for INK4b were obtained 
from the Illumina expression array, and found to be sig-
nificantly increased in tumors with CDKN2A hypermeth-
ylation (Wilcoxon rank- sum, P = 0.015; Fig. S6A). For 
TCGA samples, RNAseq data were collected for INK4b, 
which also showed a significant increase in INK4b RNA 
expression for tumors with CDKN2A hypermethylation 
(Wilcoxon rank- sum, P < 0.0001; Fig. S6B). Our finding 
of increased INK4b RNA levels in tumors with nonpro-
moter CDKN2A hypermethylation suggests an open chro-
matin conformation for at least a portion of the 9p21 
locus.
CDKN2A methylation/expression is 
associated with locoregional control
In order to examine the relationship between CDKN2A 
methylation/expression and clinical outcome, we worked 
with collaborators at the University of Pittsburgh [BD 
and JRG], Vanderbilt University [JL], and the University 
of North Carolina [NH], to retrieve clinical outcome data 
for a subset of 40 LXSCC patients included in the TCGA 
(Table S4). Using the same expression cutoffs established 
for the initial TCGA analyses, we identified 24 hypometh-
ylated and 16 hypermethylated tumors (Fig. S7). While 
the TCGA subcohort was more likely to be male, Caucasian 
and non- Hispanic, and less likely to be HPV positive 
compared to our MMC cohort, no significant associations 
were seen between nonpromoter CDKN2A methylation 
and clinicopathologic factors. RNA levels of ARF and 
INK4a were significantly higher in the hypermethylated 
vs. hypomethylated tumors from this subgroup (Wilcoxon 
rank- sum test P < 0.0001 and P = 0.005, respectively).
To evaluate the relationship between nonpromoter 
CDKN2A methylation, RNA expression and tumor 
Figure 4. Copy number variation and mutation data for TCGA LXSCC 
cohort. All 111 LXSCC from the TCGA cohort were sorted based on 
CDKN2A methylation, ARF expression, INK4a expression, CDKN2A copy 
number variation (CNV), CDKN2A mutation, and TP53 mutation status. 
Each column represents a single sample. A color key indicating CDKN2A 
methylation status (hypo vs. hyper), CDKN2A RNA expression status 
(low vs. high), CDKN2A CNV, and mutations status (CDKN2A and TP53) 
is shown on the left.
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progression, we assessed the risk of locoregional recur-
rence (LRR) for the combined cohort of (n = 69) LXSCC 
patients from MMC, Pittsburgh, Vanderbilt, and UNC 
(median follow- up of 26 months). Figure 5A shows the 
Kaplan–Meier plots for LRR comparing LXSCC patients 
with respect to nonpromoter CDKN2A methylation status. 
Patients with CDKN2A hypermethylation in the tumor 
had a lower risk of LRR when compared to those with 
hypomethylated tumors, although the results were not 
significant (Log- rank test P = 0.11). We observed similar 
differences when we assessed risk of LRR by CDKN2A 
transcript levels using median cutoff levels for ARF and 
Figure 5. Increased risk of local regional recurrence is associated with CDKN2A hypomethylation and low RNA expression. Recurrence was assessed 
for 69 LXSCC patients in the combined MMC, Pittsburgh, Vanderbilt and UNC cohort. (A) A Kaplan–Meier was generated for 42 hypomethylated 
(green, dashed line) and 27 hypermethylated tumors (red, solid line). The plotted results indicate a decreased risk of recurrence in the hypermethylated 
group (Log- rank, P = 0.11). (B) Patients were divided by ARF expression. The Kaplan–Meier was generated comparing 36 tumors with low ARF 
expression (green, dashed line) and 33 tumors with high ARF expression (red, solid line). High ARF expression was defined as a relative expression level 
≥49 (∆∆CT) for the MMC cohort and ≥171 (RPKM) for the two TCGA cohorts. The results indicate a decreased risk of recurrence in the tumors with 
high ARF expression (Log- rank test, P = 0.18). (C) Patients were divided by levels of INK4a expression. The Kaplan–Meier was generated to compare 
42 tumors with low INK4a expression (green, dashed line) and 27 tumors with high INK4a expression (red, solid line). Here high INK4a expression was 
defined as a relative expression level ≥166 (∆∆CT) for the MMC cohort and ≥35 (RPKM) for the two TCGA cohorts. High INK4a RNA expression alone 
did not contribute to a decreased risk for LRR (Log- rank, P = 0.31). (D) Patients were divided by CDKN2A methylation, but tumors with either high 
ARF or high INK4a were moved to the hypermethylated group. The Kaplan–Meier was generated comparing 27 hypomethylated tumors with low 
levels of CDKN2A expression (green, dashed line) and 42 tumors with either hypermethylation or high levels of CDKN2A expression (red, solid line). 
The results indicate a significant decreased risk of LRR in tumors with CDKN2A hypermethylation, high ARF expression, or high INK4a expression 
(Log- rank, P = 0.01). MMC, montefiore medical center.
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INK4a RNA, although these were also not significant 
(Log- rank test P = 0.18 for low vs. high ARF expression; 
Fig. 5B, and P = 0.31 for INK4A expression; Fig. 5C). 
When we further classified patients based on their com-
bined tumor CDKN2A locus methylation/expression status, 
comparing patients with either hypermethylated CDKN2A 
or high RNA levels of ARF/INK4a to those with CDKN2A 
hypomethylation and low ARF+INK4a expression, we 
found a stronger association with risk of LRR (Log- rank 
test P = 0.01; Fig. 5D).
To assess if CDKN2A hypermethylation and high ARF/
INK4a expression was associated with lower risk of LRR 
after adjustment for confounding factors, multivariable 
cox proportional hazard regression models were con-
structed. After backward selection to identify significant 
confounders, a model adjusting for treatment and other 
relevant/significant clinicopathologic factors (e.g., age, 
gender, and nodal status at diagnosis) showed that LXSCC 
patients with nonpromoter CDKN2A hypermethylation, 
high ARF expression or high INK4a expression were sig-
nificantly less likely to develop a LRR compared to patients 
lacking both nonpromoter CDKN2A methylation and RNA 
expression (adjusted hazard ratio = 0.21, 95% CI: 0.05–0.81; 
Table 1). Given the potential impact of treatment modali-
ties on locoregional control, we also assessed the subset 
(n = 48) of patients who received surgery as a component 
of their treatment, which was the most commonly used 
modality (Fig. S8). As with the expanded cohort, detec-
tion of nonpromoter CDKN2A hypermethylation or high 
ARF/INK4A expression was associated with a significantly 
lower risk of LRR (Log- rank test, P = 0.01). Our statisti-
cal analyses on clinical outcome indicate that a combined 
marker of CDKN2A methylation or expression is associ-
ated with a decreased risk of LRR for LXSCC.
Discussion
In this study, we demonstrate that methylation of the 
terminal intron/exon of the CDKN2A tumor suppressor 
gene in LXSCC is associated with increased expression 
of CDKN2A transcripts, ARF and INK4a, which are known 
to stabilize cell cycle proteins p53 and RB, respectively 
[19]. In addition, we found that hypermethylation and 
transcription of this locus was significantly associated with 
improved locoregional control in LXSCC.
We previously identified a significant relationship 
between downstream CDKN2A hypermethylation (at the 
same locus) and increased RNA expression that was also 
correlated with HPV infection in OPSCC [6]. Whereas 
HPV is prevalent in OPSCC, LXSCC is not typically asso-
ciated with HPV infection [20]. Despite this, we observed 
a significant proportion of LXSCC exhibited hypermeth-
ylation of the same nonpromoter region of CDKN2A, 
and increased levels of RNA expression, suggesting that 
the association was not limited to HPV- associated 
disease.
The CDKN2A locus is frequently altered in head and 
neck cancer, either through complete deletion of both 
transcripts or microdeletion of exons specific to ARF and/
or INK4A, or through mutation producing nonfunctional 
proteins [10]. When we compared the genetic and epige-
netic data from TCGA, we found that while CDKN2A was 
frequently mutated in LXSCC tumors, the mutations 
occurred exclusively within exon 1α (which is unique to 
INK4a) and exon 2, which is shared by both transcripts 
and essential for ARF- mediated MDM2 nucleolar transloca-
tion [21]. No mutations were found within exon 1β, which 
is unique to ARF. In addition, a number of tumors with 
high CDKN2A expression also exhibited a loss of one copy 
of CDKN2A. This is of relevance since ARF cannot stabilize 
p53 without both alleles [22], and combined with exon 2 
mutations, suggests the presence of a nonfunctional ARF- 
MDM2- p53 pathway. Furthermore, when we looked at the 
RNA expression of two downstream targets of the INK4a- 
CDK- Rb- E2F pathway, Cyclin A and Cyclin E [23, 24], 
we found similar levels in tumors independent of CDKN2A 
methylation status. This suggests the presence of active E2F 
protein despite high levels of INK4a RNA.
Whereas loss of the Rb and p53 pathways may drive 
tumorigenesis in LXSCC, high levels of ARF RNA may 
Table 1. Multivariable cox regression model evaluating the association 
between CDKN2A nonpromoter methylation or expression and time to 
locoregional recurrence.
Variable N
Hazard 
Ratio 95% CI P- value
Methylated or high expression
Negative 25 –
Positive 41 0.21 (0.05, 0.81) 0.024
Age 
<60 years old 28 –
≥ 60 years old 38 0.55 (0.12, 2.44) 0.430
Gender
Male 48 –
Female 18 0.30 (0.03, 2.76) 0.290
Nodal metastases
N0 32 –
N+ 34 1.17 (0.28, 4.89) 0.830
Treatment
Unimodality1 28 –
Surgery + adjuvant2 25 1.48 (0.27, 8,13) 0.650
Chemo- radiation 13 5.00 (0.91, 27.43) 0.064
Model stratified on institution (MMC or TCGA). Hazard ratios were mu-
tually adjusted for all other variables shown.
1Unimodality, radiation alone or surgery alone.
2Adjuvant, postoperative radiation or chemoradiation.
“–”reference category.
CI, confidence interval.
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enhance patient response to treatment by inducing apop-
tosis in tumor cells independent of p53 [25, 26]. In par-
ticular, the overexpression of ARF exon 1β alone may 
be sufficient to induce p53- indepent apoptosis [26]. Since 
exon 1β was found to be intact in all of TCGA LXSCC 
samples, we infer that tumors with high levels of ARF 
RNA may be generating some level of tumor suppression 
despite the absence of an intact p53 pathway, which 
improved locoregional control.
Unlike promoter methylation, which is associated with 
transcriptional silencing of genes [27], CpG island hyper-
methylation in nonpromoter regions has been associated 
with transcriptional activation [28]. CpG methylation pat-
terns can affect protein- DNA binding interactions and 
alter chromatin structures that control corresponding gene 
expression [29]. By altering protein- DNA interactions, 
such as methylation- sensitive CTCF protein binding, CpG 
methylation can play a role in chromatin looping [30], 
resulting in open and active regional chromatin transcrip-
tional regulation. CTCF protein binding within the 
CDKN2A/B locus (including at a site adjacent to our 
area of interest) has previously been associated with 
decreased ARF, INK4a, and INK4b transcription [31]. 
RNA expression of INK4b was associated with CDKN2A 
nonpromoter methylation in both the MMC and TCGA 
cohorts, suggesting a region of open chromatin and active 
transcription.
Although we did not investigate the potential mecha-
nisms for the associations between CDKN2A nonpromoter 
methylation and RNA expression in LXSCC tumors, we 
did validate our findings using the publicly available TCGA 
data and were able to establish a clinical relevance for 
the observations. Using TCGA data, we found that neither 
CDKN2A metylation status nor RNA expression was reflec-
tive of CNV except in the case of complete deletion (<1 
copy), which made up less than half the cases without 
CDKN2A methylation and high RNA expression. Therefore, 
it is unlikely that the observed associations were driven 
by CNV. It should be noted that the combination of our 
institutional samples with TCGA necessitated comparing 
data from different methylation and expression platforms, 
which required statistical adjustment to compare high 
versus low methylation and RNA expression. However, 
given that the same relative associations were found across 
multiple assays and specimens from the different studies, 
this suggests our findings are robust. Furthermore, the 
association between CDKN2A nonpromoter methylation 
or expression and LRR remained significant after adjust-
ment for clinicopathologic factors.
It should also be noted that this initial study did not 
assess correlation with protein levels (other than clinical 
p16 staining by IHC). While we did not see a significant 
association between p16 protein expression and prognosis 
in non- OPSCC [8], others have shown p16(INK4a) expres-
sion to be associated with improved progression- free sur-
vival in LXSCC [32]. Further independent validation is 
mandated to establish the clinical utility of our findings, 
and future studies will also need to include an assessment 
of p14(ARF) protein expression.
In conclusion, we show that nonpromoter hypermeth-
ylation of the CDKN2A downstream locus correlates with 
increased ARF and INK4a mRNA expression, and that 
activation of these CDKN2A transcripts is associated with 
improved locoregional control in LXSCC. Additional work 
is needed to elucidate the exact mechanism driving 
increased nonpromoter CDKN2A methylation and expres-
sion, and how this affects response to treatment in LXSCC.
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Supporting Information
Additional supporting information may be found in the 
online version of this article:
Figure S1. ARF and all CDKN2A variants are overex-
pressed in laryngeal tumors with downstream CDKN2A 
methylation.
Figure S2. ARF expression is associated with CDKN2A 
downstream methylation. Relative ARF expression levels 
were plotted against M- values for each CpG assayed in 
the downstream region of the CDKN2A locus. 
Figure S3. INK4a expression is associated with non-
promtoer CDKN2A methylation.
Figure S4. ARF and INK4a expression are associated 
with CDKN2A nonpromoter methylation in TCGA laryn-
geal tumors.
Figure S5. Expression of Cyclin A and Cyclin E are 
similar between hypomethylated and hypermethylated 
laryngeal tumors in TCGA.
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Figure S6. INK4b expression is increased in hypermeth-
ylated laryngeal tumors from MMC and TCGA Cohorts.
Figure S7. ARF and INK4a expression are increased in 
hypermethylated laryngeal tumors from TCGA.
Figure S8. Nonpromoter CDKN2A hypomethylation 
and low ARF/INK4a expression in tumors is associated 
with an increased risk of local regional recurrence in 
laryngeal cancer patients treated with surgery.
Table S1. Clinical data for the montefiore medical center 
cohort.
Table S2. Clinical data for the patients from the mon-
tefiore medical center cohort with qRT- PCR data.
Table S3. Clinical data for TCGA laryngeal tumors.
Table S4. Clinical data for the University of Pittsburgh, 
Vanderbilt University, and University of North Carolina 
of Chapel Hill Cohorts.
